Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 2
2013 2
2014 3
2015 2
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Cutaneous photosensitivity-lethal colitis syndrome"
Page 1
Pyostomatitis vegetans.
Hegarty AM, Barrett AW, Scully C. Hegarty AM, et al. Clin Exp Dermatol. 2004 Jan;29(1):1-7. doi: 10.1111/j.1365-2230.2004.01438.x. Clin Exp Dermatol. 2004. PMID: 14723710 Review.
Pyostomatitis vegetans is a rare oral disorder often associated with gastrointestinal and/or cutaneous diseases and sometimes with other disorders. The association of pyostomatitis vegetans with inflammatory bowel disease, particularly ulcerative colitis, is well kn …
Pyostomatitis vegetans is a rare oral disorder often associated with gastrointestinal and/or cutaneous diseases and sometimes with ot …
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Eggermont AM, et al. Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Lancet Oncol. 2015. PMID: 25840693 Clinical Trial.
METHODS: We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis 1 mm or in-transit metastasis) with adequate resection of lymph nodes (ie, the primary cutaneous melanoma must have been completely excised w …
METHODS: We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis 1 mm or …
Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Corsello SM, et al. J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75. doi: 10.1210/jc.2012-4075. Epub 2013 Mar 7. J Clin Endocrinol Metab. 2013. PMID: 23471977 Free article. Review.
However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designated as "immune-related adverse events," mainly including rash, colitis, hepatitis, and endocr …
However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmun …
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Sakakida T, et al. Clin Transl Oncol. 2020 Jun;22(6):919-927. doi: 10.1007/s12094-019-02214-8. Epub 2019 Oct 1. Clin Transl Oncol. 2020. PMID: 31576495
Four patients in the positive ANA group and 69 patients in the negative group developed irAEs of any grade without a significant difference between the groups. The development of endocrine, pulmonary, and cutaneous irAEs was not significant, whereas positive ANA was signif …
Four patients in the positive ANA group and 69 patients in the negative group developed irAEs of any grade without a significant difference …
Prevalence of pyoderma gangrenosum and Sweets syndrome in inflammatory bowel disease at a tertiary healthcare center.
Giraudo F, Miraglia E, Garbi ML, Yantorno M, Maradeo MR, Correa GJ, Tufare F. Giraudo F, et al. Rev Esp Enferm Dig. 2021 Oct;113(10):691-697. doi: 10.17235/reed.2020.7431/2020. Rev Esp Enferm Dig. 2021. PMID: 33267595 Free article.
Biological therapy was prescribed to three patients with partial response to corticosteroids and persistent intestinal disease activity. This therapy was not indicated for cutaneous manifestations only. Three patients with moderate-to-severe Crohns disease presented classi …
Biological therapy was prescribed to three patients with partial response to corticosteroids and persistent intestinal disease activity. Thi …
Mucocutaneous granulomatous disease in a patient with Hermansky-Pudlak syndrome.
Salvaggio HL, Graeber KE, Clarke LE, Schlosser BJ, Orlow SJ, Clarke JT. Salvaggio HL, et al. JAMA Dermatol. 2014 Oct;150(10):1083-7. doi: 10.1001/jamadermatol.2014.147. JAMA Dermatol. 2014. PMID: 24989352 Review.
IMPORTANCE: Hermansky-Pudlak syndrome (HPS) is a rare genodermatosis characterized by oculocutaneous albinism, platelet dysfunction, and in some patients, pulmonary fibrosis and granulomatous colitis. ...These cutaneous findings had the typical clinical and h …
IMPORTANCE: Hermansky-Pudlak syndrome (HPS) is a rare genodermatosis characterized by oculocutaneous albinism, platelet dysfunction, …
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Ma C, Armstrong AW. Ma C, et al. J Dermatolog Treat. 2014 Oct;25(5):401-8. doi: 10.3109/09546634.2013.813897. Epub 2013 Jul 3. J Dermatolog Treat. 2014. PMID: 23763243 Review.
RESULTS: Ipilimumab was associated with immune-mediated diarrhea and colitis, with an incidence rate of 0.0017 cases per 100 person-years. ...Dacarbazine was associated with respiratory toxicity and dyspnea, with incidence rates of 0.0001 and 0.00008 cases per 100 person-y …
RESULTS: Ipilimumab was associated with immune-mediated diarrhea and colitis, with an incidence rate of 0.0017 cases per 100 person-y …
Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1beta after Azathioprine Exposure: Case Report and Review of the Literature.
Imhof L, Meier B, Frei P, Kamarachev J, Rogler G, Kolios A, Navarini AA, Contassot E, French LE. Imhof L, et al. Dermatology. 2015;230(4):293-8. doi: 10.1159/000371879. Epub 2015 Mar 14. Dermatology. 2015. PMID: 25791317 Free article. Review.
Sweet's syndrome (SS) is a dermatosis with systemic symptoms characterized by tender, red nodules or papules, occasionally covered with vesicles, pustules or bullae, usually affecting the upper limbs, face and neck. SS is frequently observed in patients with leukemi …
Sweet's syndrome (SS) is a dermatosis with systemic symptoms characterized by tender, red nodules or papules, occasionally covered wi …
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Pollack MH, et al. Ann Oncol. 2018 Jan 1;29(1):250-255. doi: 10.1093/annonc/mdx642. Ann Oncol. 2018. PMID: 29045547 Free PMC article.
All were rechallenged with anti-PD-1, and 14 (18%) had recurrent irAEs at a median of 14 days after therapy resumption (six grade 1-2, seven grade 3-4, and one grade 5 Steven-Johnson Syndrome). Colitis was less likely to recur than other irAEs (6% versus 28%, P = 0. …
All were rechallenged with anti-PD-1, and 14 (18%) had recurrent irAEs at a median of 14 days after therapy resumption (six grade 1-2, seven …
Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases.
Magro CM, Porcu P, Ahmad N, Klinger D, Crowson AN, Nuovo G. Magro CM, et al. Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):216-24. doi: 10.1097/00129039-200409000-00006. Appl Immunohistochem Mol Morphol. 2004. PMID: 15551734
Therapy with local irradiation or Rituximab resulted in lesional resolution. Underlying illnesses included Sjogren's syndrome, hepatitis C, ulcerative colitis, autoimmune thyroid disease, and rheumatoid arthritis. ...In one case there was EBER staining of plasma cel …
Therapy with local irradiation or Rituximab resulted in lesional resolution. Underlying illnesses included Sjogren's syndrome, hepati …
12 results